AU2011239537A1 - Treatment of cancers having K-ras mutations - Google Patents

Treatment of cancers having K-ras mutations Download PDF

Info

Publication number: AU2011239537A1
Authority: AU; Australia
Prior art keywords: pct; compound; substituted; mmol; amino
Prior art date: 2010-04-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2011239537A

Other languages

English (en)

Inventor

Rudi Bao

Chengjung Lai

Changgeng Qian

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Curis Inc

Original Assignee

Curis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-16

Filing date

2011-04-15

Publication date

2012-11-15

2011-04-15 Application filed by Curis Inc filed Critical Curis Inc

2012-11-15 Publication of AU2011239537A1 publication Critical patent/AU2011239537A1/en

Status Abandoned legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 69
101710113436 GTPase KRas Proteins 0.000 title claims abstract description 38
230000035772 mutation Effects 0.000 title claims abstract description 32
238000011282 treatment Methods 0.000 title description 14
238000000034 method Methods 0.000 claims abstract description 211
201000011510 cancer Diseases 0.000 claims abstract description 42
239000003276 histone deacetylase inhibitor Substances 0.000 claims abstract description 25
229940121372 histone deacetylase inhibitor Drugs 0.000 claims abstract description 18
150000001875 compounds Chemical class 0.000 claims description 615
-1 LBH5 89 Chemical compound 0.000 claims description 164
125000001072 heteroaryl group Chemical group 0.000 claims description 75
125000000623 heterocyclic group Chemical group 0.000 claims description 72
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 68
125000000217 alkyl group Chemical group 0.000 claims description 62
125000001931 aliphatic group Chemical group 0.000 claims description 61
125000003118 aryl group Chemical group 0.000 claims description 58
229910052757 nitrogen Inorganic materials 0.000 claims description 45
229910052739 hydrogen Inorganic materials 0.000 claims description 39
239000001257 hydrogen Substances 0.000 claims description 37
125000003342 alkenyl group Chemical group 0.000 claims description 31
229910005965 SO 2 Inorganic materials 0.000 claims description 30
150000003839 salts Chemical class 0.000 claims description 30
108091000080 Phosphotransferase Proteins 0.000 claims description 29
102000020233 phosphotransferase Human genes 0.000 claims description 29
239000000651 prodrug Substances 0.000 claims description 27
229940002612 prodrug Drugs 0.000 claims description 27
125000002252 acyl group Chemical group 0.000 claims description 26
125000003282 alkyl amino group Chemical group 0.000 claims description 26
230000000694 effects Effects 0.000 claims description 26
150000002431 hydrogen Chemical class 0.000 claims description 26
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 26
125000003545 alkoxy group Chemical group 0.000 claims description 25
102000003964 Histone deacetylase Human genes 0.000 claims description 24
108090000353 Histone deacetylase Proteins 0.000 claims description 24
125000000304 alkynyl group Chemical group 0.000 claims description 24
125000003107 substituted aryl group Chemical group 0.000 claims description 22
125000000753 cycloalkyl group Chemical group 0.000 claims description 20
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
229940043355 kinase inhibitor Drugs 0.000 claims description 17
239000003757 phosphotransferase inhibitor Substances 0.000 claims description 17
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 17
125000004663 dialkyl amino group Chemical group 0.000 claims description 16
229910052736 halogen Inorganic materials 0.000 claims description 15
150000002367 halogens Chemical class 0.000 claims description 15
125000000714 pyrimidinyl group Chemical group 0.000 claims description 15
125000004076 pyridyl group Chemical group 0.000 claims description 14
125000000168 pyrrolyl group Chemical group 0.000 claims description 14
229910052717 sulfur Inorganic materials 0.000 claims description 14
208000006994 Precancerous Conditions Diseases 0.000 claims description 13
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 13
125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 12
230000002401 inhibitory effect Effects 0.000 claims description 12
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 10
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 9
125000004442 acylamino group Chemical group 0.000 claims description 9
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 9
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 8
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
201000002528 pancreatic cancer Diseases 0.000 claims description 6
208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
230000035755 proliferation Effects 0.000 claims description 6
WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 6
229960000237 vorinostat Drugs 0.000 claims description 6
QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
230000019491 signal transduction Effects 0.000 claims description 5
125000000547 substituted alkyl group Chemical group 0.000 claims description 5
OYYVWNDMOQPMGE-SDQBBNPISA-N (5z)-5-[[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound OC1=CC(F)=CC=C1C(O1)=CC=C1\C=C/1C(=O)NC(=O)S\1 OYYVWNDMOQPMGE-SDQBBNPISA-N 0.000 claims description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 4
HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 claims description 4
INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
108010014186 ras Proteins Proteins 0.000 claims description 4
BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 3
CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 claims description 3
208000003200 Adenoma Diseases 0.000 claims description 3
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 3
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
125000005122 aminoalkylamino group Chemical group 0.000 claims description 3
229950006418 dactolisib Drugs 0.000 claims description 3
JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 3
201000010985 invasive ductal carcinoma Diseases 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims description 3
SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 claims description 2
VLULRUCCHYVXOH-UHFFFAOYSA-N 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one Chemical compound CC1=CC=CC=C1CN1C(=O)C(CN(CC=2C=CC=CC=2)CC2)=C2N2CCN=C21 VLULRUCCHYVXOH-UHFFFAOYSA-N 0.000 claims description 2
XLJORQYAOTYVQS-OGCOKEDGSA-N 17-hydroxywortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CC[C@H](O)[C@@]2(C)C[C@H]1OC(C)=O XLJORQYAOTYVQS-OGCOKEDGSA-N 0.000 claims description 2
QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 claims description 2
230000007730 Akt signaling Effects 0.000 claims description 2
YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 claims description 2
CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims description 2
101100512897 Caenorhabditis elegans mes-2 gene Proteins 0.000 claims description 2
206010008342 Cervix carcinoma Diseases 0.000 claims description 2
206010014733 Endometrial cancer Diseases 0.000 claims description 2
206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
FCKJZIRDZMVDEM-UHFFFAOYSA-N N-(7,8-dimethoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene)pyridine-3-carboxamide Chemical compound COC1=C(C2=NC(=NC(=O)C3=CN=CC=C3)N4CCNC4=C2C=C1)OC FCKJZIRDZMVDEM-UHFFFAOYSA-N 0.000 claims description 2
TUVCWJQQGGETHL-UHFFFAOYSA-N PI-103 Chemical compound OC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 TUVCWJQQGGETHL-UHFFFAOYSA-N 0.000 claims description 2
QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 claims description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
125000005096 aminoalkylaminocarbonyl group Chemical group 0.000 claims description 2
229950003628 buparlisib Drugs 0.000 claims description 2
201000010881 cervical cancer Diseases 0.000 claims description 2
XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 claims description 2
QOXHZZQZTIGPEV-UHFFFAOYSA-K cyclopenta-1,3-diene;titanium(4+);trichloride Chemical compound Cl[Ti+](Cl)Cl.C=1C=C[CH-]C=1 QOXHZZQZTIGPEV-UHFFFAOYSA-K 0.000 claims description 2
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 2
YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims description 2
229960003445 idelalisib Drugs 0.000 claims description 2
QTHCAAFKVUWAFI-DJKKODMXSA-N n-[(e)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-n,2-dimethyl-5-nitrobenzenesulfonamide Chemical compound C=1N=C2C=CC(Br)=CN2C=1/C=N/N(C)S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1C QTHCAAFKVUWAFI-DJKKODMXSA-N 0.000 claims description 2
JLPDBLFIVFSOCC-XYXFTTADSA-N oleandrin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(C[C@@H]([C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)OC(C)=O)O)[C@]3(C)CC1 JLPDBLFIVFSOCC-XYXFTTADSA-N 0.000 claims description 2
CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 claims description 2
229910052705 radium Inorganic materials 0.000 claims description 2
OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 2
229960003452 romidepsin Drugs 0.000 claims description 2
108010091666 romidepsin Proteins 0.000 claims description 2
OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 2
229910052701 rubidium Inorganic materials 0.000 claims description 2
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 2
229960000604 valproic acid Drugs 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims 1
206010001233 Adenoma benign Diseases 0.000 claims 1
102220526729 PHD finger protein 24_H37N_mutation Human genes 0.000 claims 1
239000003112 inhibitor Substances 0.000 abstract description 11
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract description 3
229940116355 PI3 kinase inhibitor Drugs 0.000 abstract 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 abstract 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 195
239000007787 solid Substances 0.000 description 195
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 183
238000005481 NMR spectroscopy Methods 0.000 description 162
239000000203 mixture Substances 0.000 description 150
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 147
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 136
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 132
239000000243 solution Substances 0.000 description 121
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 109
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 101
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 82
238000002360 preparation method Methods 0.000 description 63
235000019441 ethanol Nutrition 0.000 description 58
229940126214 compound 3 Drugs 0.000 description 52
LZMKLGSLUKISQE-UHFFFAOYSA-N hydroxylamine;methanol Chemical compound OC.ON LZMKLGSLUKISQE-UHFFFAOYSA-N 0.000 description 50
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
235000019439 ethyl acetate Nutrition 0.000 description 46
125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 46
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 44
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 42
125000004432 carbon atom Chemical group C* 0.000 description 36
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 36
210000004027 cell Anatomy 0.000 description 33
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 31
150000003254 radicals Chemical class 0.000 description 29
239000011541 reaction mixture Substances 0.000 description 29
239000002904 solvent Substances 0.000 description 28
239000012267 brine Substances 0.000 description 26
239000003921 oil Substances 0.000 description 26
235000019198 oils Nutrition 0.000 description 26
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 25
239000011734 sodium Substances 0.000 description 25
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
239000012044 organic layer Substances 0.000 description 24
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 22
235000017557 sodium bicarbonate Nutrition 0.000 description 22
229910000030 sodium bicarbonate Inorganic materials 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
125000004429 atom Chemical group 0.000 description 21
239000003208 petroleum Substances 0.000 description 21
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
239000003795 chemical substances by application Substances 0.000 description 20
235000011056 potassium acetate Nutrition 0.000 description 20
IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 19
238000004440 column chromatography Methods 0.000 description 19
CZFSGYCLOCCASM-UHFFFAOYSA-N n-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 CZFSGYCLOCCASM-UHFFFAOYSA-N 0.000 description 19
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 18
239000003814 drug Substances 0.000 description 18
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
239000000460 chlorine Substances 0.000 description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
LXJLGYYEYXALIX-UHFFFAOYSA-N ethyl 2-[[2-(3-acetamidophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(NC(C)=O)C=CC=3)=NC(N3CCOCC3)=C2S1 LXJLGYYEYXALIX-UHFFFAOYSA-N 0.000 description 17
238000005160 1H NMR spectroscopy Methods 0.000 description 16
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
230000001588 bifunctional effect Effects 0.000 description 16
229920006395 saturated elastomer Polymers 0.000 description 16
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 15
238000010992 reflux Methods 0.000 description 15
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
239000000725 suspension Substances 0.000 description 14
101150003085 Pdcl gene Proteins 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
229940079593 drug Drugs 0.000 description 13
125000002877 alkyl aryl group Chemical group 0.000 description 12
125000005025 alkynylaryl group Chemical group 0.000 description 12
239000003937 drug carrier Substances 0.000 description 12
239000007788 liquid Substances 0.000 description 12
239000000546 pharmaceutical excipient Substances 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
125000005647 linker group Chemical group 0.000 description 11
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 11
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
239000008194 pharmaceutical composition Substances 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
125000005024 alkenyl aryl group Chemical group 0.000 description 10
125000004183 alkoxy alkyl group Chemical group 0.000 description 10
238000009472 formulation Methods 0.000 description 10
QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 9
239000002253 acid Substances 0.000 description 9
201000010099 disease Diseases 0.000 description 9
SIRUPXFAJWRELQ-UHFFFAOYSA-N ethyl 2-[2,2-dimethylpropyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CC(C)(C)C)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 SIRUPXFAJWRELQ-UHFFFAOYSA-N 0.000 description 9
SAUWUKGEDYGTQA-UHFFFAOYSA-N ethyl 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoate Chemical compound C=12SC(CN(CCCC(=O)OCC)C(=O)OC(C)(C)C)=CC2=NC(Cl)=NC=1N1CCOCC1 SAUWUKGEDYGTQA-UHFFFAOYSA-N 0.000 description 9
125000000592 heterocycloalkyl group Chemical group 0.000 description 9
125000001424 substituent group Chemical group 0.000 description 9
208000035475 disorder Diseases 0.000 description 8
BFDRQDZWKVCARB-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-(2,2-dimethylpropyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CC(C)(C)C)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 BFDRQDZWKVCARB-UHFFFAOYSA-N 0.000 description 8
QAKSSPKPCAQCAU-UHFFFAOYSA-N ethyl 6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]hexanoate Chemical compound C=12SC(CNCCCCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 QAKSSPKPCAQCAU-UHFFFAOYSA-N 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
229910000041 hydrogen chloride Inorganic materials 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
125000002911 monocyclic heterocycle group Chemical group 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
239000000843 powder Substances 0.000 description 8
QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 description 8
239000000126 substance Substances 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
KJIODOACRIRBPB-UHFFFAOYSA-N 4-bromo-1h-indazole Chemical compound BrC1=CC=CC2=C1C=NN2 KJIODOACRIRBPB-UHFFFAOYSA-N 0.000 description 7
108020004705 Codon Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
125000003710 aryl alkyl group Chemical group 0.000 description 7
239000012043 crude product Substances 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
IEMKQRSOAOPKRJ-UHFFFAOYSA-N ethyl 2-chloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1 IEMKQRSOAOPKRJ-UHFFFAOYSA-N 0.000 description 7
FQOUFMHJMYJZOF-UHFFFAOYSA-N ethyl 4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]butanoate Chemical compound C=12SC(CN(C)CCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 FQOUFMHJMYJZOF-UHFFFAOYSA-N 0.000 description 7
LCFHIEFEHWTLOF-UHFFFAOYSA-N ethyl 5-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]pentanoate Chemical compound C1CN(CCCCC(=O)OCC)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LCFHIEFEHWTLOF-UHFFFAOYSA-N 0.000 description 7
229910052943 magnesium sulfate Inorganic materials 0.000 description 7
235000019341 magnesium sulphate Nutrition 0.000 description 7
HOQPCMHERISQFY-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]propan-1-amine Chemical compound C=12SC(CNCCC)=CC2=NC(Cl)=NC=1N1CCOCC1 HOQPCMHERISQFY-UHFFFAOYSA-N 0.000 description 7
125000004430 oxygen atom Chemical group O* 0.000 description 7
239000000047 product Substances 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
238000000746 purification Methods 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
229960001866 silicon dioxide Drugs 0.000 description 7
239000003826 tablet Substances 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 6
DDGJOTNSVPHXNT-UHFFFAOYSA-N 4-[6-(bromomethyl)-2-chlorothieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(CBr)=CC2=NC(Cl)=NC=1N1CCOCC1 DDGJOTNSVPHXNT-UHFFFAOYSA-N 0.000 description 6
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
125000004171 alkoxy aryl group Chemical group 0.000 description 6
125000004414 alkyl thio group Chemical group 0.000 description 6
239000002775 capsule Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
FQBWWPNSVVYCHN-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 FQBWWPNSVVYCHN-UHFFFAOYSA-N 0.000 description 6
125000004415 heterocyclylalkyl group Chemical group 0.000 description 6
125000002883 imidazolyl group Chemical group 0.000 description 6
125000001041 indolyl group Chemical group 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
PYTWIIUKFHEGGC-UHFFFAOYSA-N methyl 6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 PYTWIIUKFHEGGC-UHFFFAOYSA-N 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
TZYNTKYTACHQAE-UHFFFAOYSA-N n-hydroxy-3-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]propanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NN(CCC(=O)NO)C=4C=CC=3)=NC(N3CCOCC3)=C2S1 TZYNTKYTACHQAE-UHFFFAOYSA-N 0.000 description 6
KPWICCCSPDNTKF-UHFFFAOYSA-N n-hydroxy-6-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]hexanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C4=CN(CCCCCC(=O)NO)N=C4C=CC=3)=NC(N3CCOCC3)=C2S1 KPWICCCSPDNTKF-UHFFFAOYSA-N 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
230000003000 nontoxic effect Effects 0.000 description 6
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
230000008569 process Effects 0.000 description 6
125000003226 pyrazolyl group Chemical group 0.000 description 6
108700042226 ras Genes Proteins 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
SPLBPPMPKQJGSP-UHFFFAOYSA-N (2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methanamine Chemical compound C=12SC(CN)=CC2=NC(Cl)=NC=1N1CCOCC1 SPLBPPMPKQJGSP-UHFFFAOYSA-N 0.000 description 5
QAFVXBQPQCSSLI-UHFFFAOYSA-N 1h-thieno[3,2-d]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC2=C1SC=C2 QAFVXBQPQCSSLI-UHFFFAOYSA-N 0.000 description 5
BZULTSHGWOGXKK-UHFFFAOYSA-N 4-[2-chloro-6-[(4-methylsulfanyloxypiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C1CN(OSC)CCN1CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 BZULTSHGWOGXKK-UHFFFAOYSA-N 0.000 description 5
108010033040 Histones Proteins 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
235000010443 alginic acid Nutrition 0.000 description 5
229920000615 alginic acid Polymers 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
238000000576 coating method Methods 0.000 description 5
229940125898 compound 5 Drugs 0.000 description 5
125000000392 cycloalkenyl group Chemical group 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
VUWBNIOBCLBZPH-UHFFFAOYSA-N ethyl 5-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]pentanoate Chemical compound C=1C=CC2=NN(CCCCC(=O)OCC)C=C2C=1C(N=C1C=C(CN2CCN(CC2)S(C)(=O)=O)SC1=1)=NC=1N1CCOCC1 VUWBNIOBCLBZPH-UHFFFAOYSA-N 0.000 description 5
125000004446 heteroarylalkyl group Chemical group 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 5
230000003211 malignant effect Effects 0.000 description 5
239000000463 material Substances 0.000 description 5
230000009401 metastasis Effects 0.000 description 5
KMAWENLAUQIUBD-UHFFFAOYSA-N methyl 5-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentanoate Chemical compound C=12SC(CN(CCCCC(=O)OC)C(=O)OC(C)(C)C)=CC2=NC(Cl)=NC=1N1CCOCC1 KMAWENLAUQIUBD-UHFFFAOYSA-N 0.000 description 5
238000001556 precipitation Methods 0.000 description 5
229940083542 sodium Drugs 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
125000004434 sulfur atom Chemical group 0.000 description 5
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 4
UJOJBFAUAVIWPP-UHFFFAOYSA-N (2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methanol Chemical compound C=12SC(CO)=CC2=NC(Cl)=NC=1N1CCOCC1 UJOJBFAUAVIWPP-UHFFFAOYSA-N 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
FGYOBHBOPXDZMF-UHFFFAOYSA-N 1-(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)-n-methylmethanamine Chemical compound C=12SC(CNC)=CC2=NC(Cl)=NC=1N1CCOCC1 FGYOBHBOPXDZMF-UHFFFAOYSA-N 0.000 description 4
AQECFYPZMBRCIA-UHFFFAOYSA-N 2,4-dichlorothieno[3,2-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2SC=CC2=N1 AQECFYPZMBRCIA-UHFFFAOYSA-N 0.000 description 4
CEAKZVDHZILFGK-UHFFFAOYSA-N 2,4-diethylpentanedioic acid Chemical compound CCC(C(O)=O)CC(CC)C(O)=O CEAKZVDHZILFGK-UHFFFAOYSA-N 0.000 description 4
HKQMXHKNXRNUCF-UHFFFAOYSA-N 4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine Chemical compound C=12SC=CC2=NC(Cl)=NC=1N1CCOCC1 HKQMXHKNXRNUCF-UHFFFAOYSA-N 0.000 description 4
NYMYGNLCILQUMT-UHFFFAOYSA-N 5-bromo-n,n-dimethylpyrimidin-2-amine Chemical compound CN(C)C1=NC=C(Br)C=N1 NYMYGNLCILQUMT-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
239000001856 Ethyl cellulose Substances 0.000 description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
229930040373 Paraformaldehyde Natural products 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
208000009956 adenocarcinoma Diseases 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
125000005213 alkyl heteroaryl group Chemical group 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
125000004104 aryloxy group Chemical group 0.000 description 4
XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
229940125758 compound 15 Drugs 0.000 description 4
229940126540 compound 41 Drugs 0.000 description 4
238000001816 cooling Methods 0.000 description 4
229960001760 dimethyl sulfoxide Drugs 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
NCEXFFIQEINAEO-VURMDHGXSA-N ethyl (z)-2-(ethoxymethyl)-3-methoxyprop-2-enoate Chemical compound CCOC\C(=C\OC)C(=O)OCC NCEXFFIQEINAEO-VURMDHGXSA-N 0.000 description 4
AGQYZUBSUHPUES-UHFFFAOYSA-N ethyl 2-[4-(aminomethyl)piperidin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCC(CN)CC1 AGQYZUBSUHPUES-UHFFFAOYSA-N 0.000 description 4
YXSRBUNPFJSJMO-UHFFFAOYSA-N ethyl 2-[4-[[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCC(CN(C)CC=2SC3=C(N4CCOCC4)N=C(Cl)N=C3C=2)CC1 YXSRBUNPFJSJMO-UHFFFAOYSA-N 0.000 description 4
UDVBSJWIOXLCBG-UHFFFAOYSA-N ethyl 2-[butyl-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxylate Chemical compound N=1C=C(C(=O)OCC)C=NC=1N(CCCC)CC(SC1=2)=CC1=NC(Cl)=NC=2N1CCOCC1 UDVBSJWIOXLCBG-UHFFFAOYSA-N 0.000 description 4
CFWYVWBOCSWZIK-UHFFFAOYSA-N ethyl 2-oxo-1h-pyrimidine-5-carboxylate Chemical compound CCOC(=O)C=1C=NC(=O)NC=1 CFWYVWBOCSWZIK-UHFFFAOYSA-N 0.000 description 4
DYEUWQNJWMPQAL-UHFFFAOYSA-N ethyl 2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CNC(=O)NC1 DYEUWQNJWMPQAL-UHFFFAOYSA-N 0.000 description 4
BJOXQFPCSUMLQN-UHFFFAOYSA-N ethyl 4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoate Chemical compound C=12SC(CN(CCCC(=O)OCC)C(=O)OC(C)(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 BJOXQFPCSUMLQN-UHFFFAOYSA-N 0.000 description 4
MCCCGPGDWFCQBQ-UHFFFAOYSA-N ethyl 5-[4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]piperazin-1-yl]pentanoate Chemical compound C1CN(CCCCC(=O)OCC)CCN1CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 MCCCGPGDWFCQBQ-UHFFFAOYSA-N 0.000 description 4
ZYEHTUIHXNUXEW-UHFFFAOYSA-N ethyl 6-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]hexanoate Chemical compound C=12SC(CNCCCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 ZYEHTUIHXNUXEW-UHFFFAOYSA-N 0.000 description 4
GGJPCRDVYPJJFB-UHFFFAOYSA-N ethyl 6-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]hexanoate Chemical compound C=1C=CC2=NN(CCCCCC(=O)OCC)C=C2C=1C(N=C1C=C(CN2CCN(CC2)S(C)(=O)=O)SC1=1)=NC=1N1CCOCC1 GGJPCRDVYPJJFB-UHFFFAOYSA-N 0.000 description 4
235000019325 ethyl cellulose Nutrition 0.000 description 4
229920001249 ethyl cellulose Polymers 0.000 description 4
239000000284 extract Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229940014259 gelatin Drugs 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
239000008187 granular material Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
125000004449 heterocyclylalkenyl group Chemical group 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
XXHOHJTVFUJJMT-UHFFFAOYSA-N n-(3-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(Br)=C1 XXHOHJTVFUJJMT-UHFFFAOYSA-N 0.000 description 4
CGTZXRLVHFZVIE-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]-2,2-dimethylpropan-1-amine Chemical compound C=12SC(CNCC(C)(C)C)=CC2=NC(Cl)=NC=1N1CCOCC1 CGTZXRLVHFZVIE-UHFFFAOYSA-N 0.000 description 4
HFBWKMAPDOQZNZ-UHFFFAOYSA-N n-hydroxy-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-(2-methoxyethyl)amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CCOC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 HFBWKMAPDOQZNZ-UHFFFAOYSA-N 0.000 description 4
WAZYFRLJFZVEQM-UHFFFAOYSA-N n-hydroxy-2-[[2-(3-hydroxyphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(O)C=CC=1)=NC=2N1CCOCC1 WAZYFRLJFZVEQM-UHFFFAOYSA-N 0.000 description 4
PMKSWLPJTZBVNA-UHFFFAOYSA-N n-hydroxy-2-[[2-[4-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=CC(CO)=CC=1)=NC=2N1CCOCC1 PMKSWLPJTZBVNA-UHFFFAOYSA-N 0.000 description 4
RXWSTGJYPIFWPA-UHFFFAOYSA-N n-hydroxy-2-[methyl-[(4-morpholin-4-yl-2-pyridin-3-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC=CC=1)=NC=2N1CCOCC1 RXWSTGJYPIFWPA-UHFFFAOYSA-N 0.000 description 4
MNKGAFXPZNKRLL-UHFFFAOYSA-N n-hydroxy-2-[methyl-[(4-morpholin-4-yl-2-pyrimidin-5-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC=NC=1)=NC=2N1CCOCC1 MNKGAFXPZNKRLL-UHFFFAOYSA-N 0.000 description 4
OHSHEUPWMYCFNS-UHFFFAOYSA-N n-hydroxy-7-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]heptanamide Chemical compound C=12SC(CN(CCCCCCC(=O)NO)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 OHSHEUPWMYCFNS-UHFFFAOYSA-N 0.000 description 4
230000009826 neoplastic cell growth Effects 0.000 description 4
239000000346 nonvolatile oil Substances 0.000 description 4
229920002866 paraformaldehyde Polymers 0.000 description 4
239000002245 particle Substances 0.000 description 4
235000021317 phosphate Nutrition 0.000 description 4
239000006187 pill Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
235000012239 silicon dioxide Nutrition 0.000 description 4
239000007921 spray Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
239000001993 wax Substances 0.000 description 4
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
LQEQVVBJQZOHHD-UHFFFAOYSA-N (2-bromophenyl)methyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1Br LQEQVVBJQZOHHD-UHFFFAOYSA-N 0.000 description 3
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 3
OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 3
REHYBWIGNLPYTA-JXMROGBWSA-N (e)-n-hydroxy-3-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]phenyl]prop-2-enamide Chemical compound C=1C=C(\C=C\C(=O)NO)C=CC=1N(C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 REHYBWIGNLPYTA-JXMROGBWSA-N 0.000 description 3
SJUUPNNMQDIXIP-RMKNXTFCSA-N (e)-n-hydroxy-3-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]phenyl]prop-2-enamide Chemical compound C1=CC(/C=C/C(=O)NO)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 SJUUPNNMQDIXIP-RMKNXTFCSA-N 0.000 description 3
BZYGFMKYRKQSQG-UHFFFAOYSA-N 1-bromo-3-(methoxymethyl)benzene Chemical compound COCC1=CC=CC(Br)=C1 BZYGFMKYRKQSQG-UHFFFAOYSA-N 0.000 description 3
VZPRVBGCPFNJMO-UHFFFAOYSA-N 1-methylsulfanyloxypiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CSON1CCNCC1 VZPRVBGCPFNJMO-UHFFFAOYSA-N 0.000 description 3
QLXXLGBOXDYBGI-UHFFFAOYSA-N 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]ethanol Chemical compound C=12SC(CNCCO)=CC2=NC(Cl)=NC=1N1CCOCC1 QLXXLGBOXDYBGI-UHFFFAOYSA-N 0.000 description 3
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 3
ROXIFDKIQYPVCY-UHFFFAOYSA-N 2-[[2-(2-amino-4-methylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C(=NC(N)=NC=1)C)=NC=2N1CCOCC1 ROXIFDKIQYPVCY-UHFFFAOYSA-N 0.000 description 3
HAHQWFVYINSSIG-UHFFFAOYSA-N 2-[[2-(3-acetamidophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(NC(C)=O)C=CC=1)=NC=2N1CCOCC1 HAHQWFVYINSSIG-UHFFFAOYSA-N 0.000 description 3
DSONSPJGTUIWAF-UHFFFAOYSA-N 2-[[2-(3-aminophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(N)C=CC=1)=NC=2N1CCOCC1 DSONSPJGTUIWAF-UHFFFAOYSA-N 0.000 description 3
ZQFAPAMHVSXWMY-UHFFFAOYSA-N 2-[[2-(6-aminopyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC(N)=CC=1)=NC=2N1CCOCC1 ZQFAPAMHVSXWMY-UHFFFAOYSA-N 0.000 description 3
BLKMBNOEZWSRGU-UHFFFAOYSA-N 2-[[2-[2-(dimethylamino)pyrimidin-5-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound C1=NC(N(C)C)=NC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 BLKMBNOEZWSRGU-UHFFFAOYSA-N 0.000 description 3
DFNQUKGIDCSUPW-UHFFFAOYSA-N 2-[[2-[3-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(CN)C=CC=1)=NC=2N1CCOCC1 DFNQUKGIDCSUPW-UHFFFAOYSA-N 0.000 description 3
DTPBBEDURXHSOM-UHFFFAOYSA-N 2-[[2-[3-(dimethylamino)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound CN(C)C1=CC=CC(C=2N=C3C=C(CN(C)C=4N=CC(=CN=4)C(=O)NO)SC3=C(N3CCOCC3)N=2)=C1 DTPBBEDURXHSOM-UHFFFAOYSA-N 0.000 description 3
IUVUCGHQOBTKLT-UHFFFAOYSA-N 2-[[2-[4-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=CC(CN)=CC=1)=NC=2N1CCOCC1 IUVUCGHQOBTKLT-UHFFFAOYSA-N 0.000 description 3
GZGOLDVPLRYKGK-UHFFFAOYSA-N 2-[butyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CCCC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 GZGOLDVPLRYKGK-UHFFFAOYSA-N 0.000 description 3
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 3
WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 3
DSYSVUWIAUMZDQ-UHFFFAOYSA-N 3-bromo-5-fluoro-2-methylaniline Chemical compound CC1=C(N)C=C(F)C=C1Br DSYSVUWIAUMZDQ-UHFFFAOYSA-N 0.000 description 3
ODJFDWIECLJWSR-UHFFFAOYSA-N 3-bromobenzamide Chemical compound NC(=O)C1=CC=CC(Br)=C1 ODJFDWIECLJWSR-UHFFFAOYSA-N 0.000 description 3
YRPXZCWDXBNPBD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC2=C1C=NN2 YRPXZCWDXBNPBD-UHFFFAOYSA-N 0.000 description 3
XRCUWYHURKQUIX-UHFFFAOYSA-N 4-[2-chloro-6-(piperazin-1-ylmethyl)thieno[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12SC(CN3CCNCC3)=CC2=NC(Cl)=NC=1N1CCOCC1 XRCUWYHURKQUIX-UHFFFAOYSA-N 0.000 description 3
VUKKRGQLFZMXNZ-UHFFFAOYSA-N 4-bromo-6-fluoro-1h-indazole Chemical compound FC1=CC(Br)=C2C=NNC2=C1 VUKKRGQLFZMXNZ-UHFFFAOYSA-N 0.000 description 3
SQOJDBHJUUGQJP-UHFFFAOYSA-N 5-bromo-2-ethylpyrimidine Chemical compound CCC1=NC=C(Br)C=N1 SQOJDBHJUUGQJP-UHFFFAOYSA-N 0.000 description 3
NEDJTEXNSTUKHW-UHFFFAOYSA-N 5-bromo-2-methylpyrimidine Chemical compound CC1=NC=C(Br)C=N1 NEDJTEXNSTUKHW-UHFFFAOYSA-N 0.000 description 3
UDQGIOYIJKRLFH-UHFFFAOYSA-N 5-bromo-n-methylpyrimidin-2-amine Chemical compound CNC1=NC=C(Br)C=N1 UDQGIOYIJKRLFH-UHFFFAOYSA-N 0.000 description 3
GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 3
229920002907 Guar gum Polymers 0.000 description 3
241000282412 Homo Species 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 3
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
102000038030 PI3Ks Human genes 0.000 description 3
108091007960 PI3Ks Proteins 0.000 description 3
229910002666 PdCl2 Inorganic materials 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
108091008611 Protein Kinase B Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
208000024770 Thyroid neoplasm Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000000783 alginic acid Substances 0.000 description 3
229960001126 alginic acid Drugs 0.000 description 3
150000004781 alginic acids Chemical class 0.000 description 3
125000005217 alkenylheteroaryl group Chemical group 0.000 description 3
125000004948 alkyl aryl alkyl group Chemical group 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
125000005018 aryl alkenyl group Chemical group 0.000 description 3
125000005015 aryl alkynyl group Chemical group 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 3
150000003936 benzamides Chemical class 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
229960001631 carbomer Drugs 0.000 description 3
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
230000024245 cell differentiation Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
229940075614 colloidal silicon dioxide Drugs 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
229940125797 compound 12 Drugs 0.000 description 3
229940126543 compound 14 Drugs 0.000 description 3
229940125936 compound 42 Drugs 0.000 description 3
229940126545 compound 53 Drugs 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
229940099112 cornstarch Drugs 0.000 description 3
239000006071 cream Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
QFNOUPAKTVGXKG-RMKNXTFCSA-N ethyl (e)-3-[4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1N(C)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 QFNOUPAKTVGXKG-RMKNXTFCSA-N 0.000 description 3
LPCXIPFIONKCLI-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-(2-hydroxyethyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CCO)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 LPCXIPFIONKCLI-UHFFFAOYSA-N 0.000 description 3
CACKLWNGDUDAEB-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-(2-methoxyethyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CCOC)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 CACKLWNGDUDAEB-UHFFFAOYSA-N 0.000 description 3
QGYZVWQCNLRYPQ-UHFFFAOYSA-N ethyl 2-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-(2-methylpropyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CC(C)C)CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 QGYZVWQCNLRYPQ-UHFFFAOYSA-N 0.000 description 3
AIYAYPKLVPBNQR-UHFFFAOYSA-N ethyl 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-(2-methoxyethyl)amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(CCOC)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 AIYAYPKLVPBNQR-UHFFFAOYSA-N 0.000 description 3
TUVSWNFMUMLSLP-UHFFFAOYSA-N ethyl 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-propylamino]pyrimidine-5-carboxylate Chemical compound N=1C=C(C(=O)OCC)C=NC=1N(CCC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 TUVSWNFMUMLSLP-UHFFFAOYSA-N 0.000 description 3
QLMMAQVFJCVMQB-UHFFFAOYSA-N ethyl 2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 QLMMAQVFJCVMQB-UHFFFAOYSA-N 0.000 description 3
ZMZMEHOHPOEHSR-UHFFFAOYSA-N ethyl 2-[[2-[3-(dimethylamino)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(C=CC=3)N(C)C)=NC(N3CCOCC3)=C2S1 ZMZMEHOHPOEHSR-UHFFFAOYSA-N 0.000 description 3
TXEYIHWEDAZOBE-UHFFFAOYSA-N ethyl 2-[butyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N=1C=C(C(=O)OCC)C=NC=1N(CCCC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 TXEYIHWEDAZOBE-UHFFFAOYSA-N 0.000 description 3
GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
XKHBPDUDFXDHBG-UHFFFAOYSA-N ethyl 6-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]hexanoate Chemical compound C=12SC(CN(C)CCCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 XKHBPDUDFXDHBG-UHFFFAOYSA-N 0.000 description 3
UZLWHEFMAQSNEQ-UHFFFAOYSA-N ethyl 6-[4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]piperazin-1-yl]hexanoate Chemical compound C1CN(CCCCCC(=O)OCC)CCN1CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 UZLWHEFMAQSNEQ-UHFFFAOYSA-N 0.000 description 3
JPEDQRIYRDULPN-UHFFFAOYSA-N ethyl 6-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]hexanoate Chemical compound C1CN(CCCCCC(=O)OCC)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 JPEDQRIYRDULPN-UHFFFAOYSA-N 0.000 description 3
OTLZEKFFEVFHSV-UHFFFAOYSA-N ethyl 6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]hexanoate Chemical compound C=12SC(CN(C)CCCCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 OTLZEKFFEVFHSV-UHFFFAOYSA-N 0.000 description 3
DXBULVYHTICWKT-UHFFFAOYSA-N ethyl 6-bromohexanoate Chemical compound CCOC(=O)CCCCCBr DXBULVYHTICWKT-UHFFFAOYSA-N 0.000 description 3
XBDOBUVAIHMWEU-UHFFFAOYSA-N ethyl 7-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]heptanoate Chemical compound C=12SC(CN(C)CCCCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 XBDOBUVAIHMWEU-UHFFFAOYSA-N 0.000 description 3
VRFWBAUFHPFHQQ-UHFFFAOYSA-N ethyl 7-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]heptanoate Chemical compound C=12SC(CNCCCCCCC(=O)OCC)=CC2=NC(Cl)=NC=1N1CCOCC1 VRFWBAUFHPFHQQ-UHFFFAOYSA-N 0.000 description 3
UGHBQUSJIAVHMN-UHFFFAOYSA-N ethyl 7-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]heptanoate Chemical compound C1=CC=C2N(CCCCCCC(=O)OCC)N=CC2=C1C(N=C1C=C(CN2CCN(CC2)S(C)(=O)=O)SC1=1)=NC=1N1CCOCC1 UGHBQUSJIAVHMN-UHFFFAOYSA-N 0.000 description 3
XFEXWLRFFMUVPL-UHFFFAOYSA-N ethyl 7-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]heptanoate Chemical compound C1CN(CCCCCCC(=O)OCC)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 XFEXWLRFFMUVPL-UHFFFAOYSA-N 0.000 description 3
WMCGQYUCWPJPIG-UHFFFAOYSA-N ethyl 7-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]heptanoate Chemical compound C=12SC(CN(C)CCCCCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 WMCGQYUCWPJPIG-UHFFFAOYSA-N 0.000 description 3
CXJDJFMMCPSTFU-UHFFFAOYSA-N ethyl 7-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]heptanoate Chemical compound C=12SC(CNCCCCCCC(=O)OCC)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 CXJDJFMMCPSTFU-UHFFFAOYSA-N 0.000 description 3
230000029142 excretion Effects 0.000 description 3
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000000665 guar gum Substances 0.000 description 3
235000010417 guar gum Nutrition 0.000 description 3
229960002154 guar gum Drugs 0.000 description 3
230000036541 health Effects 0.000 description 3
125000004447 heteroarylalkenyl group Chemical group 0.000 description 3
125000005312 heteroarylalkynyl group Chemical group 0.000 description 3
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
239000005457 ice water Substances 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
XMXUJDFHPVOABU-UHFFFAOYSA-N methyl 2-[[2-[3-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(CN)C=CC=3)=NC(N3CCOCC3)=C2S1 XMXUJDFHPVOABU-UHFFFAOYSA-N 0.000 description 3
NNOYNOFEXBGPIU-UHFFFAOYSA-N methyl 2-[[2-[4-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OC)=CN=C1N(C)CC1=CC2=NC(C=3C=CC(CN)=CC=3)=NC(N3CCOCC3)=C2S1 NNOYNOFEXBGPIU-UHFFFAOYSA-N 0.000 description 3
MYNCNLJWMBYMLQ-UHFFFAOYSA-N methyl 5-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl-methylamino]pentanoate Chemical compound C=12SC(CN(C)CCCCC(=O)OC)=CC2=NC(Cl)=NC=1N1CCOCC1 MYNCNLJWMBYMLQ-UHFFFAOYSA-N 0.000 description 3
YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 3
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
ZDQZRIXKDPITGG-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]-2-methoxyethanamine Chemical compound C=12SC(CNCCOC)=CC2=NC(Cl)=NC=1N1CCOCC1 ZDQZRIXKDPITGG-UHFFFAOYSA-N 0.000 description 3
DIYXXWCZYVTSAB-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]-2-methylpropan-1-amine Chemical compound C=12SC(CNCC(C)C)=CC2=NC(Cl)=NC=1N1CCOCC1 DIYXXWCZYVTSAB-UHFFFAOYSA-N 0.000 description 3
RUZSAERWZSIPBC-UHFFFAOYSA-N n-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]butan-1-amine Chemical compound C=12SC(CNCCCC)=CC2=NC(Cl)=NC=1N1CCOCC1 RUZSAERWZSIPBC-UHFFFAOYSA-N 0.000 description 3
UVPIDNMBEZYIIU-UHFFFAOYSA-N n-[(3-bromophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(Br)=C1 UVPIDNMBEZYIIU-UHFFFAOYSA-N 0.000 description 3
HBBBWKUVJSIFKV-UHFFFAOYSA-N n-[(4-bromophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=C(Br)C=C1 HBBBWKUVJSIFKV-UHFFFAOYSA-N 0.000 description 3
YDKPXUYTOCEYIB-UHFFFAOYSA-N n-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]acetamide Chemical compound C1=CC(CNC(=O)C)=CC=C1B1OC(C)(C)C(C)(C)O1 YDKPXUYTOCEYIB-UHFFFAOYSA-N 0.000 description 3
PQDVDZVHXAMKJG-UHFFFAOYSA-N n-hydroxy-2-[2-hydroxyethyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CCO)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 PQDVDZVHXAMKJG-UHFFFAOYSA-N 0.000 description 3
ZKAWXBWMUHZUOX-UHFFFAOYSA-N n-hydroxy-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-(2-methylpropyl)amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CC(C)C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 ZKAWXBWMUHZUOX-UHFFFAOYSA-N 0.000 description 3
GZAPMNSRALRNRF-UHFFFAOYSA-N n-hydroxy-2-[[2-(3-methoxyphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound COC1=CC=CC(C=2N=C3C=C(CN(C)C=4N=CC(=CN=4)C(=O)NO)SC3=C(N3CCOCC3)N=2)=C1 GZAPMNSRALRNRF-UHFFFAOYSA-N 0.000 description 3
DKNQJZZPXCRQBX-UHFFFAOYSA-N n-hydroxy-2-[[2-[2-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C(=CC=CC=1)CO)=NC=2N1CCOCC1 DKNQJZZPXCRQBX-UHFFFAOYSA-N 0.000 description 3
CAKVTYSJPFVWCT-UHFFFAOYSA-N n-hydroxy-2-[[2-[3-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(CO)C=CC=1)=NC=2N1CCOCC1 CAKVTYSJPFVWCT-UHFFFAOYSA-N 0.000 description 3
VEEQZIRXFALOMR-UHFFFAOYSA-N n-hydroxy-2-[methyl-[[2-(2-methylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC(C)=NC=1)=NC=2N1CCOCC1 VEEQZIRXFALOMR-UHFFFAOYSA-N 0.000 description 3
XEDJNRNYKQMESF-UHFFFAOYSA-N n-hydroxy-4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 XEDJNRNYKQMESF-UHFFFAOYSA-N 0.000 description 3
RBEKXPMXZFXYON-UHFFFAOYSA-N n-hydroxy-6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]hexanamide Chemical compound C=12SC(CN(CCCCCC(=O)NO)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 RBEKXPMXZFXYON-UHFFFAOYSA-N 0.000 description 3
USUKHNWASJITKV-UHFFFAOYSA-N n-hydroxy-6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]hexanamide Chemical compound C=12SC(CNCCCCCC(=O)NO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 USUKHNWASJITKV-UHFFFAOYSA-N 0.000 description 3
FKEFYPSFROAUKX-UHFFFAOYSA-N n-hydroxy-7-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]heptanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C4=CN(CCCCCCC(=O)NO)N=C4C=CC=3)=NC(N3CCOCC3)=C2S1 FKEFYPSFROAUKX-UHFFFAOYSA-N 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
150000003906 phosphoinositides Chemical class 0.000 description 3
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
229960004063 propylene glycol Drugs 0.000 description 3
108060006633 protein kinase Proteins 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
102000016914 ras Proteins Human genes 0.000 description 3
230000009467 reduction Effects 0.000 description 3
208000011581 secondary neoplasm Diseases 0.000 description 3
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
229960002930 sirolimus Drugs 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
229940032147 starch Drugs 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
235000013616 tea Nutrition 0.000 description 3
FTUGDRKBXMMROC-UHFFFAOYSA-N tert-butyl 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 FTUGDRKBXMMROC-UHFFFAOYSA-N 0.000 description 3
VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
FSWNRRSWFBXQCL-UHFFFAOYSA-N (3-bromophenyl)methanol Chemical compound OCC1=CC=CC(Br)=C1 FSWNRRSWFBXQCL-UHFFFAOYSA-N 0.000 description 2
NCNYEGJDGNOYJX-NSCUHMNNSA-N (e)-2,3-dibromo-4-oxobut-2-enoic acid Chemical compound OC(=O)C(\Br)=C(/Br)C=O NCNYEGJDGNOYJX-NSCUHMNNSA-N 0.000 description 2
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
DMKREZLZDOSDQU-UHFFFAOYSA-N 2-(3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COC1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 DMKREZLZDOSDQU-UHFFFAOYSA-N 0.000 description 2
BQIKAHULWVZWPU-UHFFFAOYSA-N 2-(benzylamino)chromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C=C1NCC1=CC=CC=C1 BQIKAHULWVZWPU-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
FDTVLJCTUKZTMS-UHFFFAOYSA-N 2-[3-(methoxymethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COCC1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 FDTVLJCTUKZTMS-UHFFFAOYSA-N 0.000 description 2
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
COBZMDPXIDGRHY-UHFFFAOYSA-N 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound C1=NC(C)=NC=C1B1OC(C)(C)C(C)(C)O1 COBZMDPXIDGRHY-UHFFFAOYSA-N 0.000 description 2
KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
FBZSEJLLDVYGSZ-UHFFFAOYSA-N 2-morpholin-4-yl-8-phenylmethoxychromen-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1OCC1=CC=CC=C1 FBZSEJLLDVYGSZ-UHFFFAOYSA-N 0.000 description 2
IVKCFMPZKYEGBK-UHFFFAOYSA-N 2-morpholin-4-yl-9-(pyridin-3-ylmethoxy)pyrido[1,2-a]pyrimidin-4-one Chemical compound C=1C=CN2C(=O)C=C(N3CCOCC3)N=C2C=1OCC1=CC=CN=C1 IVKCFMPZKYEGBK-UHFFFAOYSA-N 0.000 description 2
VDMRPNTZWKDYBB-UHFFFAOYSA-N 2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound N1=C2C=CC=CN2C(=O)C=C1N1CCOCC1 VDMRPNTZWKDYBB-UHFFFAOYSA-N 0.000 description 2
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
MUKIFYQKIZOYKT-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(O)=C1 MUKIFYQKIZOYKT-UHFFFAOYSA-N 0.000 description 2
IILVSKMKMOJHMA-UHFFFAOYSA-N 3-bromo-2-methylaniline Chemical compound CC1=C(N)C=CC=C1Br IILVSKMKMOJHMA-UHFFFAOYSA-N 0.000 description 2
BIJWOCITWIWQLC-UHFFFAOYSA-N 3-methyl-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound N1=C2C=CC=CN2C(=O)C(C)=C1N1CCOCC1 BIJWOCITWIWQLC-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
SYJMHOBGFXCKRG-UHFFFAOYSA-N 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine Chemical compound CC1=NC(N)=NC=C1B1OC(C)(C)C(C)(C)O1 SYJMHOBGFXCKRG-UHFFFAOYSA-N 0.000 description 2
YFTAUNOLAHRUIE-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)N=C1 YFTAUNOLAHRUIE-UHFFFAOYSA-N 0.000 description 2
BPQVMIDUTRJYSC-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=C(N)N=C1 BPQVMIDUTRJYSC-UHFFFAOYSA-N 0.000 description 2
VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
FTBWYCGHGSATOE-UHFFFAOYSA-N 5-bromo-2-ethylpyrimidine-4-carboxylic acid Chemical compound CCC1=NC=C(Br)C(C(O)=O)=N1 FTBWYCGHGSATOE-UHFFFAOYSA-N 0.000 description 2
MDERWSRHRJUWNS-UHFFFAOYSA-N 5-bromo-2-methylpyrimidine-4-carboxylic acid Chemical compound CC1=NC=C(Br)C(C(O)=O)=N1 MDERWSRHRJUWNS-UHFFFAOYSA-N 0.000 description 2
LPQVTZJEIXYDQA-UHFFFAOYSA-N 5-bromo-4-methylpyrimidin-2-amine Chemical compound CC1=NC(N)=NC=C1Br LPQVTZJEIXYDQA-UHFFFAOYSA-N 0.000 description 2
UHRHPPKWXSNZLR-UHFFFAOYSA-N 5-bromopyrimidin-2-amine Chemical compound NC1=NC=C(Br)C=N1 UHRHPPKWXSNZLR-UHFFFAOYSA-N 0.000 description 2
OTZMRGFPBXSAKG-UHFFFAOYSA-N 6-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(F)=CC2=C1C=NN2 OTZMRGFPBXSAKG-UHFFFAOYSA-N 0.000 description 2
NUFQTVKZZVRLAW-UHFFFAOYSA-N 8-(2-fluorophenyl)-2-morpholin-4-yl-1h-quinolin-4-one Chemical compound FC1=CC=CC=C1C1=CC=CC2=C1NC(N1CCOCC1)=CC2=O NUFQTVKZZVRLAW-UHFFFAOYSA-N 0.000 description 2
VWUOLZVKYIOWMD-UHFFFAOYSA-N 8-(3-chlorophenoxy)-2-morpholin-4-ylchromen-4-one Chemical compound ClC1=CC=CC(OC=2C3=C(C(C=C(O3)N3CCOCC3)=O)C=CC=2)=C1 VWUOLZVKYIOWMD-UHFFFAOYSA-N 0.000 description 2
MHFWTFWRBOGPGH-UHFFFAOYSA-N 8-(3-methylphenyl)-2-morpholin-4-yl-1h-quinolin-4-one Chemical compound CC1=CC=CC(C=2C3=C(C(C=C(N3)N3CCOCC3)=O)C=CC=2)=C1 MHFWTFWRBOGPGH-UHFFFAOYSA-N 0.000 description 2
BWTPNSFEPOGLDT-UHFFFAOYSA-N 8-(4-fluoro-2-methylphenoxy)-2-morpholin-4-ylchromen-4-one Chemical compound CC1=CC(F)=CC=C1OC1=CC=CC2=C1OC(N1CCOCC1)=CC2=O BWTPNSFEPOGLDT-UHFFFAOYSA-N 0.000 description 2
BBPLUKPNVSISTA-UHFFFAOYSA-N 8-anilino-2-morpholin-4-ylchromen-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1NC1=CC=CC=C1 BBPLUKPNVSISTA-UHFFFAOYSA-N 0.000 description 2
XNDOAFNGHIXHPI-UHFFFAOYSA-N 8-benzyl-2-morpholin-4-ylchromen-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1CC1=CC=CC=C1 XNDOAFNGHIXHPI-UHFFFAOYSA-N 0.000 description 2
UBJVUQITODDUCW-UHFFFAOYSA-N 9-(benzylamino)-7-methyl-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound C12=NC(N3CCOCC3)=CC(=O)N2C=C(C)C=C1NCC1=CC=CC=C1 UBJVUQITODDUCW-UHFFFAOYSA-N 0.000 description 2
QBPHVDALVMRNRH-UHFFFAOYSA-N 9-[(4-chlorophenyl)methylamino]-7-methyl-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound C12=NC(N3CCOCC3)=CC(=O)N2C=C(C)C=C1NCC1=CC=C(Cl)C=C1 QBPHVDALVMRNRH-UHFFFAOYSA-N 0.000 description 2
RHFIIAFWVZFBMT-UHFFFAOYSA-N 9-benzyl-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound C=1C=CN2C(=O)C=C(N3CCOCC3)N=C2C=1CC1=CC=CC=C1 RHFIIAFWVZFBMT-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
RFLHBLWLFUFFDZ-UHFFFAOYSA-N BML-210 Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 RFLHBLWLFUFFDZ-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108010077544 Chromatin Proteins 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102100038715 Histone deacetylase 8 Human genes 0.000 description 2
101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
229920002732 Polyanhydride Polymers 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
229920001710 Polyorthoester Polymers 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010045362 Serum Globulins Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
GZZBZWITJNATOD-UHFFFAOYSA-N [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(CO)C=C1 GZZBZWITJNATOD-UHFFFAOYSA-N 0.000 description 2
229940022663 acetate Drugs 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
239000012346 acetyl chloride Substances 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
150000001252 acrylic acid derivatives Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
125000004103 aminoalkyl group Chemical group 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
238000003782 apoptosis assay Methods 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229960003094 belinostat Drugs 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
229940054066 benzamide antipsychotics Drugs 0.000 description 2
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
235000019437 butane-1,3-diol Nutrition 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
235000011089 carbon dioxide Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000032823 cell division Effects 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000003483 chromatin Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
229940126142 compound 16 Drugs 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
229940043264 dodecyl sulfate Drugs 0.000 description 2
230000007783 downstream signaling Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
DNQDFYFSMYUFMU-FMIVXFBMSA-N ethyl (e)-3-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1N(C)CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 DNQDFYFSMYUFMU-FMIVXFBMSA-N 0.000 description 2
FAUKJUCTMOIXNO-UHFFFAOYSA-N ethyl 2-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CC1 FAUKJUCTMOIXNO-UHFFFAOYSA-N 0.000 description 2
HXZNQJDNUWCJHY-UHFFFAOYSA-N ethyl 2-[[2-(2-aminopyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 HXZNQJDNUWCJHY-UHFFFAOYSA-N 0.000 description 2
MIGWJYBFTLKLOL-UHFFFAOYSA-N ethyl 2-[[2-(2-ethylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(CC)=NC=3)=NC(N3CCOCC3)=C2S1 MIGWJYBFTLKLOL-UHFFFAOYSA-N 0.000 description 2
XQGYOWDOXLWEFO-UHFFFAOYSA-N ethyl 2-[[2-(3-hydroxyphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(O)C=CC=3)=NC(N3CCOCC3)=C2S1 XQGYOWDOXLWEFO-UHFFFAOYSA-N 0.000 description 2
SPCKLCJFCNDNIB-UHFFFAOYSA-N ethyl 2-[[2-(3-methoxyphenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(OC)C=CC=3)=NC(N3CCOCC3)=C2S1 SPCKLCJFCNDNIB-UHFFFAOYSA-N 0.000 description 2
VFHBISXAIQCGSQ-UHFFFAOYSA-N ethyl 2-[[2-(6-aminopyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(N)=CC=3)=NC(N3CCOCC3)=C2S1 VFHBISXAIQCGSQ-UHFFFAOYSA-N 0.000 description 2
ONZDGTIFPRNBHV-UHFFFAOYSA-N ethyl 2-[[2-(6-fluoro-1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=4C=NNC=4C=C(F)C=3)=NC(N3CCOCC3)=C2S1 ONZDGTIFPRNBHV-UHFFFAOYSA-N 0.000 description 2
MKVSOTQWUZQPFX-UHFFFAOYSA-N ethyl 2-[[2-[2-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C(=CC=CC=3)CO)=NC(N3CCOCC3)=C2S1 MKVSOTQWUZQPFX-UHFFFAOYSA-N 0.000 description 2
FUKSLNAEIGFUIE-UHFFFAOYSA-N ethyl 2-[[2-[3-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(CO)C=CC=3)=NC(N3CCOCC3)=C2S1 FUKSLNAEIGFUIE-UHFFFAOYSA-N 0.000 description 2
YONDQZJYPVGDSZ-UHFFFAOYSA-N ethyl 2-[[2-[3-(methoxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=C(COC)C=CC=3)=NC(N3CCOCC3)=C2S1 YONDQZJYPVGDSZ-UHFFFAOYSA-N 0.000 description 2
WHAWZNUURUQDAP-UHFFFAOYSA-N ethyl 2-[[2-[4-(hydroxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=CC(CO)=CC=3)=NC(N3CCOCC3)=C2S1 WHAWZNUURUQDAP-UHFFFAOYSA-N 0.000 description 2
PMDDZTZMZLEPHK-UHFFFAOYSA-N ethyl 2-[methyl-[(4-morpholin-4-yl-2-pyridin-3-ylthieno[3,2-d]pyrimidin-6-yl)methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC=CC=3)=NC(N3CCOCC3)=C2S1 PMDDZTZMZLEPHK-UHFFFAOYSA-N 0.000 description 2
BKQQNTZRYZEKOQ-UHFFFAOYSA-N ethyl 2-[methyl-[[2-(2-methylpyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxylate Chemical compound N1=CC(C(=O)OCC)=CN=C1N(C)CC1=CC2=NC(C=3C=NC(C)=NC=3)=NC(N3CCOCC3)=C2S1 BKQQNTZRYZEKOQ-UHFFFAOYSA-N 0.000 description 2
BZOOUMSCSPSRRF-UHFFFAOYSA-N ethyl 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NCC1=CC2=NC(Cl)=NC(N3CCOCC3)=C2S1 BZOOUMSCSPSRRF-UHFFFAOYSA-N 0.000 description 2
MCHVFQATGDYRLZ-UHFFFAOYSA-N ethyl 4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 MCHVFQATGDYRLZ-UHFFFAOYSA-N 0.000 description 2
AFRWBGJRWRHQOV-UHFFFAOYSA-N ethyl 5-bromopentanoate Chemical compound CCOC(=O)CCCCBr AFRWBGJRWRHQOV-UHFFFAOYSA-N 0.000 description 2
BOWFAHZTARBHQD-UHFFFAOYSA-N ethyl 7-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-2-yl]heptanoate Chemical compound C=1C=CC2=NN(CCCCCCC(=O)OCC)C=C2C=1C(N=C1C=C(CN2CCN(CC2)S(C)(=O)=O)SC1=1)=NC=1N1CCOCC1 BOWFAHZTARBHQD-UHFFFAOYSA-N 0.000 description 2
229960004667 ethyl cellulose Drugs 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
229940093471 ethyl oleate Drugs 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
108010074605 gamma-Globulins Proteins 0.000 description 2
239000008103 glucose Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229940071676 hydroxypropylcellulose Drugs 0.000 description 2
238000002513 implantation Methods 0.000 description 2
PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
230000007794 irritation Effects 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000012528 membrane Substances 0.000 description 2
RUZLIIJDZBWWSA-UHFFFAOYSA-N methyl 2-[1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-UHFFFAOYSA-N 0.000 description 2
TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
PKDBSOOYVOEUQR-UHFFFAOYSA-N mucobromic acid Natural products OC1OC(=O)C(Br)=C1Br PKDBSOOYVOEUQR-UHFFFAOYSA-N 0.000 description 2
RMPRVJCNMPFBCX-UHFFFAOYSA-N n,n-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine Chemical compound C1=NC(N(C)C)=NC=C1B1OC(C)(C)C(C)(C)O1 RMPRVJCNMPFBCX-UHFFFAOYSA-N 0.000 description 2
QBBYRWAXWMJNNO-UHFFFAOYSA-N n-hydroxy-2-[methyl-[[2-[2-(methylamino)pyrimidin-5-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide Chemical compound C1=NC(NC)=NC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 QBBYRWAXWMJNNO-UHFFFAOYSA-N 0.000 description 2
QDOXNCAIXITTKA-UHFFFAOYSA-N n-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine Chemical compound C1=NC(NC)=NC=C1B1OC(C)(C)C(C)(C)O1 QDOXNCAIXITTKA-UHFFFAOYSA-N 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
230000006548 oncogenic transformation Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000001301 oxygen Chemical group 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
AEABQBMUYZBBCW-UHFFFAOYSA-N pentanamide Chemical compound CC[CH]CC(N)=O AEABQBMUYZBBCW-UHFFFAOYSA-N 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000002304 perfume Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
238000002953 preparative HPLC Methods 0.000 description 2
230000005522 programmed cell death Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
DFWRZHZPJJAJMX-UHFFFAOYSA-N propanimidamide;hydrochloride Chemical compound Cl.CCC(N)=N DFWRZHZPJJAJMX-UHFFFAOYSA-N 0.000 description 2
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical class C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
229960003010 sodium sulfate Drugs 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000011593 sulfur Chemical group 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000003831 tetrazolyl group Chemical group 0.000 description 2
RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000000844 transformation Methods 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
239000008096 xylene Substances 0.000 description 2
229910052727 yttrium Inorganic materials 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
QYYZXEPEVBXNNA-QGZVFWFLSA-N (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1[C@H](C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O QYYZXEPEVBXNNA-QGZVFWFLSA-N 0.000 description 1
IOWGHQGLUMEZKG-UHFFFAOYSA-N (2-bromophenyl)methanol Chemical compound OCC1=CC=CC=C1Br IOWGHQGLUMEZKG-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
UGEQUCUBWNAUJS-UHFFFAOYSA-N (3-bromophenyl)methanamine;hydrochloride Chemical compound Cl.NCC1=CC=CC(Br)=C1 UGEQUCUBWNAUJS-UHFFFAOYSA-N 0.000 description 1
XRNVSPDQTPVECU-UHFFFAOYSA-N (4-bromophenyl)methanamine Chemical compound NCC1=CC=C(Br)C=C1 XRNVSPDQTPVECU-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
ZVDFTBJXUXQPAU-UHFFFAOYSA-N 1-bromo-5-fluoro-2-methyl-3-nitrobenzene Chemical compound CC1=C(Br)C=C(F)C=C1[N+]([O-])=O ZVDFTBJXUXQPAU-UHFFFAOYSA-N 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
101150072531 10 gene Proteins 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
WKJOQYHMXRVQDK-UHFFFAOYSA-N 2-(dimethylamino)acetamide Chemical compound CN(C)CC(N)=O WKJOQYHMXRVQDK-UHFFFAOYSA-N 0.000 description 1
GHCFWKFREBNSPC-UHFFFAOYSA-N 2-Amino-4-methylpyrimidine Chemical compound CC1=CC=NC(N)=N1 GHCFWKFREBNSPC-UHFFFAOYSA-N 0.000 description 1
OXVNXMRYVMCDCA-UHFFFAOYSA-N 2-[2,2-dimethylpropyl-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CC(C)(C)C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 OXVNXMRYVMCDCA-UHFFFAOYSA-N 0.000 description 1
ZIPBZSLLZVMHDP-UHFFFAOYSA-N 2-[[2-(2-aminopyrimidin-5-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=NC(N)=NC=1)=NC=2N1CCOCC1 ZIPBZSLLZVMHDP-UHFFFAOYSA-N 0.000 description 1
ZIHHBEUIDDYOKK-UHFFFAOYSA-N 2-[[2-(3,4-diaminophenyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(N)C(N)=CC=1)=NC=2N1CCOCC1 ZIHHBEUIDDYOKK-UHFFFAOYSA-N 0.000 description 1
RQZWOUUGADXLAW-UHFFFAOYSA-N 2-[[2-(6-fluoro-1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=C(F)C=1)=NC=2N1CCOCC1 RQZWOUUGADXLAW-UHFFFAOYSA-N 0.000 description 1
SVOYUVRUKOEDKS-UHFFFAOYSA-N 2-[[2-[3-(aminomethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxylic acid Chemical compound N=1C=C(C(O)=O)C=NC=1N(C)CC(SC1=2)=CC1=NC(C=1C=C(CN)C=CC=1)=NC=2N1CCOCC1 SVOYUVRUKOEDKS-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
PFAKZIZFIXKDFP-UHFFFAOYSA-N 2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carbaldehyde Chemical compound C=12SC(C=O)=CC2=NC(Cl)=NC=1N1CCOCC1 PFAKZIZFIXKDFP-UHFFFAOYSA-N 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
AESRWWTWEGTKGL-UHFFFAOYSA-N 2-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound C1=NC(CC)=NC=C1B1OC(C)(C)C(C)(C)O1 AESRWWTWEGTKGL-UHFFFAOYSA-N 0.000 description 1
RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical class CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
USEXQPWLCGBYNT-UHFFFAOYSA-N 3-bromo-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(Br)=C1 USEXQPWLCGBYNT-UHFFFAOYSA-N 0.000 description 1
DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
MXWDSZWTBOCWBK-UHFFFAOYSA-N 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Chemical compound CN(C)C1=CC=C(C(=O)NCCCCCCC(=O)NO)C=C1 MXWDSZWTBOCWBK-UHFFFAOYSA-N 0.000 description 1
GPIJEJLGYBWEGA-UHFFFAOYSA-N 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]butanoic acid Chemical compound C=12SC(CNCCCC(=O)O)=CC2=NC(Cl)=NC=1N1CCOCC1 GPIJEJLGYBWEGA-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
SKWTUNAAJNDEIK-UHFFFAOYSA-N 4-fluoro-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(F)C=C1[N+]([O-])=O SKWTUNAAJNDEIK-UHFFFAOYSA-N 0.000 description 1
BLOIUFYKQCCAGP-UHFFFAOYSA-N 5-aminopentanoic acid;hydron;chloride Chemical compound Cl.NCCCCC(O)=O BLOIUFYKQCCAGP-UHFFFAOYSA-N 0.000 description 1
WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
RMYDYIDGGSILID-UHFFFAOYSA-N 7-aminoheptanoic acid;hydrochloride Chemical compound Cl.NCCCCCCC(O)=O RMYDYIDGGSILID-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
235000003276 Apios tuberosa Nutrition 0.000 description 1
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
101100123574 Arabidopsis thaliana HDA19 gene Proteins 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229940078581 Bone resorption inhibitor Drugs 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000011727 Caspases Human genes 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
102100035427 Forkhead box protein O1 Human genes 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
102100039788 GTPase NRas Human genes 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
101150083200 HDA1 gene Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
102100034523 Histone H4 Human genes 0.000 description 1
102000003893 Histone acetyltransferases Human genes 0.000 description 1
108090000246 Histone acetyltransferases Proteins 0.000 description 1
102100039996 Histone deacetylase 1 Human genes 0.000 description 1
102100038720 Histone deacetylase 9 Human genes 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
101000877727 Homo sapiens Forkhead box protein O1 Proteins 0.000 description 1
101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 description 1
101001019134 Ilyobacter polytropus (strain ATCC 51220 / DSM 2926 / LMG 16218 / CuHBu1) Homoserine O-acetyltransferase 1 Proteins 0.000 description 1
101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
108010033104 M-81 Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
241000233805 Phoenix Species 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
102000010995 Pleckstrin homology domains Human genes 0.000 description 1
108050001185 Pleckstrin homology domains Proteins 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
101150040459 RAS gene Proteins 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
101100297422 Schizosaccharomyces pombe (strain 972 / ATCC 24843) phd1 gene Proteins 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108050002485 Sirtuin Proteins 0.000 description 1
102000011990 Sirtuin Human genes 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
241000862969 Stella Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108010074506 Transfer Factor Proteins 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
FDZYUTLLMOCRNT-UHFFFAOYSA-N [2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1B1OC(C)(C)C(C)(C)O1 FDZYUTLLMOCRNT-UHFFFAOYSA-N 0.000 description 1
ZEWWJJQAFTXUIS-UHFFFAOYSA-N [3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(CO)=C1 ZEWWJJQAFTXUIS-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003321 amplification Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000002102 aryl alkyloxo group Chemical group 0.000 description 1
125000005128 aryl amino alkyl group Chemical group 0.000 description 1
125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
150000005840 aryl radicals Chemical class 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000005164 aryl thioalkyl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000002617 bone density conservation agent Substances 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
150000004648 butanoic acid derivatives Chemical class 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical group [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940045200 cardioprotective agent Drugs 0.000 description 1
239000012659 cardioprotective agent Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000002113 chemopreventative effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000004927 clay Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
238000013329 compounding Methods 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
230000006196 deacetylation Effects 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
NRPMBSHHBFFYBF-VMPITWQZSA-N ethyl (e)-3-(4-aminophenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(N)C=C1 NRPMBSHHBFFYBF-VMPITWQZSA-N 0.000 description 1
BHXIWUJLHYHGSJ-UHFFFAOYSA-N ethyl 3-ethoxypropanoate Chemical compound CCOCCC(=O)OCC BHXIWUJLHYHGSJ-UHFFFAOYSA-N 0.000 description 1
IHNFPRYBRIQIAJ-UHFFFAOYSA-N ethyl 4-aminobutanoate ethyl 4-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methylamino]butanoate hydrochloride Chemical compound Cl.NCCCC(=O)OCC.ClC=1N=C(C2=C(N1)C=C(S2)CNCCCC(=O)OCC)N2CCOCC2 IHNFPRYBRIQIAJ-UHFFFAOYSA-N 0.000 description 1
MMSVBKQTXSDWQN-UHFFFAOYSA-N ethyl 6-aminohexanoate;hydron;chloride Chemical compound Cl.CCOC(=O)CCCCCN MMSVBKQTXSDWQN-UHFFFAOYSA-N 0.000 description 1
FIKVWPJKNMTBBD-UHFFFAOYSA-N ethyl 6-aminopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(N)N=C1 FIKVWPJKNMTBBD-UHFFFAOYSA-N 0.000 description 1
OOBFNDGMAGSNKA-UHFFFAOYSA-N ethyl 7-bromoheptanoate Chemical compound CCOC(=O)CCCCCCBr OOBFNDGMAGSNKA-UHFFFAOYSA-N 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
230000004907 flux Effects 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000012458 free base Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
230000003862 health status Effects 0.000 description 1
SONSSPAQDOLYEQ-UHFFFAOYSA-N heptanamide Chemical compound CCCCC[CH]C(N)=O SONSSPAQDOLYEQ-UHFFFAOYSA-N 0.000 description 1
125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000006195 histone acetylation Effects 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000005917 in vivo anti-tumor Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
229940099563 lactobionic acid Drugs 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229940049920 malate Drugs 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000008172 membrane trafficking Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
229940012189 methyl orange Drugs 0.000 description 1
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
229950007812 mocetinostat Drugs 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000003039 myelosuppressive effect Effects 0.000 description 1
GMSKIJHLMVLDSE-UHFFFAOYSA-N n-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 GMSKIJHLMVLDSE-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
ATYRNODNUVIWBG-UHFFFAOYSA-N n-hydroxy-2-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCN(CC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CC1 ATYRNODNUVIWBG-UHFFFAOYSA-N 0.000 description 1
GXYREYVTSFNGJF-UHFFFAOYSA-N n-hydroxy-2-[4-[[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide Chemical compound C=1C2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2SC=1CN(C)CC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 GXYREYVTSFNGJF-UHFFFAOYSA-N 0.000 description 1
XONGAZPJJPHEKC-UHFFFAOYSA-N n-hydroxy-2-[4-[[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCC(CNCC=2SC3=C(N4CCOCC4)N=C(N=C3C=2)C=2C=3C=NNC=3C=CC=2)CC1 XONGAZPJJPHEKC-UHFFFAOYSA-N 0.000 description 1
IEHFCERFRUFCDV-UHFFFAOYSA-N n-hydroxy-2-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-propylamino]pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NO)C=NC=1N(CCC)CC(SC1=2)=CC1=NC(C=1C=3C=NNC=3C=CC=1)=NC=2N1CCOCC1 IEHFCERFRUFCDV-UHFFFAOYSA-N 0.000 description 1
MRTLGVFZAYBGEY-UHFFFAOYSA-N n-hydroxy-2-[[2-[3-(methoxymethyl)phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound COCC1=CC=CC(C=2N=C3C=C(CN(C)C=4N=CC(=CN=4)C(=O)NO)SC3=C(N3CCOCC3)N=2)=C1 MRTLGVFZAYBGEY-UHFFFAOYSA-N 0.000 description 1
MTTHZYPWLCJLNC-OAHLLOKOSA-N n-hydroxy-2-[[2-[3-[(1r)-1-hydroxyethyl]phenyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C[C@@H](O)C1=CC=CC(C=2N=C3C=C(CN(C)C=4N=CC(=CN=4)C(=O)NO)SC3=C(N3CCOCC3)N=2)=C1 MTTHZYPWLCJLNC-OAHLLOKOSA-N 0.000 description 1
YNWYTDNDNHEVSO-UHFFFAOYSA-N n-hydroxy-4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]butanamide Chemical compound C=12SC(CNCCCC(=O)NO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 YNWYTDNDNHEVSO-UHFFFAOYSA-N 0.000 description 1
PZCFAXKRBOEWTP-UHFFFAOYSA-N n-hydroxy-5-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]pentanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NN(CCCCC(=O)NO)C=4C=CC=3)=NC(N3CCOCC3)=C2S1 PZCFAXKRBOEWTP-UHFFFAOYSA-N 0.000 description 1
MTYDYVQJQYVOIU-UHFFFAOYSA-N n-hydroxy-5-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]pentanamide Chemical compound C1CN(CCCCC(=O)NO)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 MTYDYVQJQYVOIU-UHFFFAOYSA-N 0.000 description 1
CWBGPHFJRJDOCC-UHFFFAOYSA-N n-hydroxy-6-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]hexanamide Chemical compound C1CN(CCCCCC(=O)NO)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 CWBGPHFJRJDOCC-UHFFFAOYSA-N 0.000 description 1
NMCVAWFPRVBSQC-UHFFFAOYSA-N n-hydroxy-6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)NO)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 NMCVAWFPRVBSQC-UHFFFAOYSA-N 0.000 description 1
COGZWVGUOTWAJW-UHFFFAOYSA-N n-hydroxy-6-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]amino]hexanamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(NCCCCCC(=O)NO)=C2)C2=N1 COGZWVGUOTWAJW-UHFFFAOYSA-N 0.000 description 1
WAGWMOSMPPGBDC-UHFFFAOYSA-N n-hydroxy-7-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]heptanamide Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NN(CCCCCCC(=O)NO)C=4C=CC=3)=NC(N3CCOCC3)=C2S1 WAGWMOSMPPGBDC-UHFFFAOYSA-N 0.000 description 1
GKFKMAZEWYPJAM-UHFFFAOYSA-N n-hydroxy-7-[4-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]heptanamide Chemical compound C1CN(CCCCCCC(=O)NO)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 GKFKMAZEWYPJAM-UHFFFAOYSA-N 0.000 description 1
FFUNNUWCOYEYHG-UHFFFAOYSA-N n-hydroxy-7-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]heptanamide Chemical compound C=12SC(CNCCCCCCC(=O)NO)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 FFUNNUWCOYEYHG-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
QRGHOAATPOLDPF-VQFNDLOPSA-N nanatinostat Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H]([C@@H]2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-VQFNDLOPSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
201000004228 ovarian endometrial cancer Diseases 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
229960005184 panobinostat Drugs 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
VEDDBHYQWFOITD-UHFFFAOYSA-N para-bromobenzyl alcohol Chemical compound OCC1=CC=C(Br)C=C1 VEDDBHYQWFOITD-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229940067626 phosphatidylinositols Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920001987 poloxamine Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
JUDRXQZHONTBBN-UHFFFAOYSA-N propan-2-yl 6-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methylamino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC(C)C)=CC=C1NCC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 JUDRXQZHONTBBN-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
FXJZOUPFQNMFOR-UHFFFAOYSA-N pyrimidin-2-ylboronic acid Chemical compound OB(O)C1=NC=CC=N1 FXJZOUPFQNMFOR-UHFFFAOYSA-N 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
150000003246 quinazolines Chemical class 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
229950010654 quisinostat Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
208000011571 secondary malignant neoplasm Diseases 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940056729 sodium sulfate anhydrous Drugs 0.000 description 1
XZPVPNZTYPUODG-UHFFFAOYSA-M sodium;chloride;dihydrate Chemical compound O.O.[Na+].[Cl-] XZPVPNZTYPUODG-UHFFFAOYSA-M 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
125000004426 substituted alkynyl group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960000235 temsirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
DXJJURFOCLURRH-UHFFFAOYSA-N tert-butyl n-[4-(hydroxyamino)-4-oxobutyl]-n-[[2-(1h-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]carbamate Chemical compound C=12SC(CN(CCCC(=O)NO)C(=O)OC(C)(C)C)=CC2=NC(C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 DXJJURFOCLURRH-UHFFFAOYSA-N 0.000 description 1
CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
239000010936 titanium Substances 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
208000010576 undifferentiated carcinoma Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004474 valine Substances 0.000 description 1
235000014393 valine Nutrition 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
235000014692 zinc oxide Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2011239537A 2010-04-16 2011-04-15 Treatment of cancers having K-ras mutations Abandoned AU2011239537A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US32491210P	2010-04-16	2010-04-16
US61/324,912		2010-04-16
PCT/US2011/032683 WO2011130628A1 (fr)	2010-04-16	2011-04-15	Traitement de cancers présentant des mutations k-ras

Publications (1)

Publication Number	Publication Date
AU2011239537A1 true AU2011239537A1 (en)	2012-11-15

Family

ID=44799046

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2011239537A Abandoned AU2011239537A1 (en)	2010-04-16	2011-04-15	Treatment of cancers having K-ras mutations

Country Status (6)

Country	Link
EP (1)	EP2557923A4 (fr)
JP (1)	JP2013525308A (fr)
CN (1)	CN102970868A (fr)
AU (1)	AU2011239537A1 (fr)
CA (1)	CA2795952A1 (fr)
WO (1)	WO2011130628A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2009002927A (es) *	2006-09-15	2009-03-31	Pfizer Prod Inc	Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
DK2385832T3 (en)	2009-01-08	2015-09-21	Curis Inc	Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
SI3111938T1 (sl)	2011-04-01	2019-08-30	Curis, Inc.	Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
CA2855446C (fr)	2011-11-23	2021-04-20	Cancer Research Technology Limited	Inhibiteurs de type thienopyrimidine de proteines kinases c atypiques
US8940742B2 (en) *	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP6441910B2 (ja) *	2013-09-30	2018-12-19	シャンハイインリファーマシューティカルカンパニーリミティド	縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
US9403779B2 (en) *	2013-10-08	2016-08-02	Acetylon Pharmaceuticals, Inc.	Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
CN110669047A (zh) *	2013-11-15	2020-01-10	昂克希尔迪克斯有限公司	用于治疗癌症的化合物、其组合物及应用方法
CN103601745B (zh) *	2013-11-26	2017-01-18	大连联化化学有限公司	一种通用的乙酰氨基吡啶硼酸频哪醇酯的制备方法
HUE049013T2 (hu) *	2014-03-31	2020-08-28	Scripps Research Inst	Farmakofór trail indukcióra
CN104131034B (zh) *	2014-06-19	2017-04-05	中山大学	一种嵌合载体及其制备方法和应用
EP3250034B1 (fr)	2015-01-30	2020-03-11	Basf Se	Phénylpyrimidines herbicides
JP6518833B2 (ja) *	2015-04-21	2019-05-22	▲貴▼州百▲霊▼企▲業▼集▲団▼制▲薬▼股▲分▼有限公司ＧｕｉｚｈｏｕＢａｉｌｉｎｇＧｒｏｕｐＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	プリニル−ｎ−ヒドロキシルピリミジンホルムアミド誘導体、並びにその調製方法および使用
CN105037345B (zh) *	2015-06-09	2019-01-25	天津渤海职业技术学院	抗肿瘤化合物、其制备方法和用途
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CA3034010A1 (fr)	2016-08-24	2018-03-01	Arqule, Inc.	Composes amino-pyrrolopyrimidinone et leurs procedes d'utilisation
EP3521290A4 (fr)	2016-09-29	2020-04-22	Daiichi Sankyo Company, Limited	Cristaux de [2-(1-méthyl-1h-pyrazol-4-yl)-6-(morpholin-4-yl)-9h-purin-8-yl][4-(morpholin-4-yl)pipéridin-1-yl]méthanone et sel pharmaceutiquement acceptable de celle-ci
EP3679027A1 (fr) *	2017-09-04	2020-07-15	C4 Therapeutics, Inc.	Dihydrobenzimidazolones
EP3694511A1 (fr) *	2017-10-13	2020-08-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polythérapie du cancer du pancréas
JP2021528368A (ja) *	2018-05-10	2021-10-21	ユニヴァーシティー・オブ・ルイスヴィル・リサーチ・ファウンデイション・インコーポレーテッド	Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法
WO2020055840A1 (fr)	2018-09-11	2020-03-19	Curis Inc.	Polythérapie avec un inhibiteur de phosphoinositide 3-kinase ayant une fraction de liaison au zinc
US20230078755A1 (en)	2018-12-19	2023-03-16	Shy Therapeutics, Llc	Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
EP3935050A4 (fr)	2019-03-06	2023-01-04	C4 Therapeutics, Inc.	Composés hétérocycliques pour traitement médical
MX2022013984A (es)	2020-05-08	2023-01-30	Halia Therapeutics Inc	Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
CA3180686A1 (fr) *	2020-06-04	2021-12-09	Baskaran Pillai	Nouvelles petites molecules pour la degradation ciblee de kras ne pouvant etre cible dans une therapie anticancereuse
CN113735830A (zh) *	2021-10-11	2021-12-03	成都自豪药业有限公司	一类羟肟酸衍生物及其应用
WO2024041519A1 (fr) *	2022-08-24	2024-02-29	上海璎黎药业有限公司	Composé morpholinyl quinazoline, composition pharmaceutique et utilisation associée

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1362675B (it) *	2005-03-15	2009-06-25	Menarini Internat Operations Luxembourg Sa	N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
BRPI0717907A2 (pt) *	2006-12-07	2013-11-05	Genentech Inc	"composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
AU2007334343A1 (en) *	2006-12-15	2008-06-26	Ordway Research Institute, Inc.	Treatments of therapy-resistant diseases comprising drug combinations
WO2008100985A2 (fr) *	2007-02-15	2008-08-21	Novartis Ag	Combinaisons d'agents thérapeutiques pour le traitement du cancer
WO2009129335A2 (fr) *	2008-04-15	2009-10-22	Pharmacyclics, Inc.	Inhibiteurs sélectifs de l'histone désacétylase
WO2009155659A1 (fr) *	2008-06-27	2009-12-30	The University Of Queensland	Polythérapie
DK2385832T3 (en) *	2009-01-08	2015-09-21	Curis Inc	Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel

2011
- 2011-04-15 CN CN2011800290564A patent/CN102970868A/zh active Pending
- 2011-04-15 AU AU2011239537A patent/AU2011239537A1/en not_active Abandoned
- 2011-04-15 JP JP2013505177A patent/JP2013525308A/ja active Pending
- 2011-04-15 WO PCT/US2011/032683 patent/WO2011130628A1/fr active Application Filing
- 2011-04-15 CA CA2795952A patent/CA2795952A1/fr not_active Abandoned
- 2011-04-15 EP EP11769663.3A patent/EP2557923A4/fr not_active Withdrawn

Also Published As

Publication number	Publication date
CA2795952A1 (fr)	2011-10-20
CN102970868A (zh)	2013-03-13
EP2557923A1 (fr)	2013-02-20
JP2013525308A (ja)	2013-06-20
WO2011130628A1 (fr)	2011-10-20
EP2557923A4 (fr)	2013-10-23

Legal Events

Date	Code	Title	Description
2014-12-18	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted

Publication	Publication Date	Title
AU2011239537A1 (en)	2012-11-15	Treatment of cancers having K-ras mutations
US10894795B2 (en)	2021-01-19	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
AU2009312464B2 (en)	2015-04-16	Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
US20130102595A1 (en)	2013-04-25	Treatment of cancers having k-ras mutations
AU2013206342A1 (en)	2013-07-04	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety